Publications Repository

Publications Repository

View item 
  •   Home
  • ICR Divisions
  • Cancer Biology
  • View item
  • Home
  • ICR Divisions
  • Cancer Biology
  • View item
JavaScript is disabled for your browser. Some features of this site may not work without it.

Talimogene Laherparepvec and Pembrolizumab in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (MASTERKEY-232): A Multicenter, Phase 1b Study.

Thumbnail
View/Open
Accepted version (492.7Kb)
ICR Author
Harrington, Kevin
Author
Harrington, KJ
Kong, A
Mach, N
Chesney, JA
Fernandez, BC
Rischin, D
Cohen, EEW
Radcliffe, H-S
Gumuscu, B
Cheng, J
Snyder, W
Siu, LL
Show allShow less
Type
Journal Article
Metadata
Show full item record
Abstract
Purpose The prognosis for patients with recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC) is poor, and only a minority of patients benefit from checkpoint immunotherapy. Talimogene laherparepvec (T-VEC), an oncolytic immunotherapy approved for advanced melanoma, in combination with pembrolizumab may yield enhanced antitumor activity over either agent alone.Patients and methods This was a phase Ib/III, multicenter trial testing intratumoral T-VEC combined with intravenous pembrolizumab in R/M HNSCC refractory to platinum-based chemotherapy. For phase Ib, primary endpoint was incidence of dose-limiting toxicity (DLT). Key secondary endpoints included objective response rate and progression-free survival per irRECIST, overall survival, and safety.Results Thirty-six patients were enrolled into the phase Ib study. The data cut-off date was August 28, 2018. Median follow-up was 5.8 months (range, 0.3-24.2). One DLT of T-VEC-related fatal arterial hemorrhage was reported. Twenty (55.6%) and 21 (58.3%) patients experienced adverse events (AE) related to T-VEC and pembrolizumab, respectively. Besides the DLT, there were no treatment-related fatal AEs. A confirmed partial response was observed in 5 (13.9%) patients. Ten (27.8%) patients were unevaluable for response due to early death. Median PFS and OS were 3.0 months [95% confidence interval (Cl), 2.0-5.8] and 5.8 months (95% Cl, 2.9-11.4), respectively.Conclusions The combination of T-VEC and pembrolizumab demonstrated a tolerable safety profile in R/M HNSCC. The efficacy with the combination was similar to that with pembrolizumab monotherapy in historical HNSCC studies. Phase III part of this study was not further pursued (ClinicalTrials.gov Identifier: NCT02626000).
URI
https://repository.icr.ac.uk/handle/internal/4429
DOI
https://doi.org/10.1158/1078-0432.ccr-20-1170
Collections
  • Cancer Biology
  • Radiotherapy and Imaging
Research team
Targeted Therapy
Targeted Therapy
Language
eng
Date accepted
2020-07-09
Citation
Clinical cancer research : an official journal of the American Association for Cancer Research, 2020, 26 (19), pp. 5153 - 5161

Browse

All of ICR repositoryICR DivisionsBy issue dateAuthorsTitlesPublication TypesThis collectionBy issue dateAuthorsTitlesPublication Types
  • Login
  • Registered office: The Institute of Cancer Research, 123 Old Brompton Road, London, SW7 3RP
    A Charity, Not for Profit. Company Limited by Guarantee.
    Registered in England No. 534147. VAT Registration No. GB 849 0581 02.